ArticleBlood advances2025

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.

Nausheen Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.